Rheolytic therapy combined with intragraft abciximab for treatment in acute myocardial infarction.
نویسندگان
چکیده
After coronary artery bypass graft (CABG) surgery, patients can present with challenging lesions in the setting of acute coronary syndrome, particularly with high clot burden. Techniques including thrombectomy and local delivery of glycoprotein IIb/IIIa inhibitors have been utilized for these saphenous venous graft lesions. We report a case involving a post-CABG patient presenting with an acute ST-segment elevation myocardial infarction due to great clot burden in his bypass graft and successful restoration of thrombolysis in myocardial infarction (TIMI) grade 3 flow after rheolytic thrombectomy followed by localized IIb/IIIa administration.
منابع مشابه
Fasting and medical issues during Ramadan.
1. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344: 1888-1894. 2. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigato...
متن کاملReperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
BACKGROUND Plasminogen activator therapy for acute myocardial infarction is limited by lack of achievement of early, complete, and sustained reperfusion in a substantial proportion of patients. Many phase II trials have supported the potential of combined fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition for improving reperfusion. We did a randomised, open-label trial to compar...
متن کاملCombination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.
BACKGROUND Use of abciximab in combination with administration of thrombolytics has been shown to improve epicardial and microvascular coronary blood flow in acute myocardial infarction (AMI). As a potential mechanism, we hypothesized that combination therapy would reduce angiographically evident thrombus (AET) and would increase lumen diameter compared with thrombolytic monotherapy. METHODS ...
متن کاملThe use of abciximab associated with primary angioplasty for treating acute myocardial infarction.
OBJECTIVE To assess the benefit resulting from the use of abciximab associated with primary angioplasty. The following parameters were analyzed in-hospital, at 30 days, and 6 months: (a) flow in the culprit artery; (b) ventricular function; (c) combined outcome of death, acute myocardial infarction, and additional revascularization. METHODS From November 1997 to June 1999, a longitudinal nonr...
متن کاملAggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study.
BACKGROUND AND PURPOSE A combined therapy of local recombinant tissue plasminogen activator (rtPA) fibrinolysis and intravenous Abciximab platelet inhibition with additional percutaneous transluminal angioplasty (PTA)/stenting may improve recanalization and neurological outcome in patients with acute vertebrobasilar occlusion. METHODS Combined FAST therapy consisted on intravenous bolus of Ab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of invasive cardiology
دوره 25 2 شماره
صفحات -
تاریخ انتشار 2013